Medtronic Elevates 2027 Forecasts Amid Surge in Heart Device Demand
Medtronic raises fiscal 2027 outlook with strong cardiovascular device sales and strategic investments.
Medtronic has boosted its fiscal 2027 financial forecasts, citing robust demand for its heart devices that are increasingly used in complex cardiovascular procedures. The medical technology giant has updated its revenue growth expectations, now projecting an annual organic increase of 7.25% to 7.75%, up from its previous forecast of 6.75% to 7.25%.
Investment in Innovative Technologies
In a move to strengthen its portfolio, Medtronic announced an $80 million investment in Pi-Cardia, a company specializing in heart-valve repair devices, with an option to acquire it for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States.
Geoff Martha, Medtronic's CEO, highlighted the strategic importance of these investments, stating that they align with the company's focus on high-growth segments within the medical technology sector. Martha noted the potential for significant expansion in soft tissue robotic surgery, particularly in emerging markets where penetration remains below 1%.
Strong Quarterly Performance
Medtronic's cardiovascular segment reported a notable 19.5% increase in quarterly sales, reaching $3.93 billion. This surge was driven by an 88% growth in its pulsed field ablation portfolio, a device used to treat irregular heart rhythms. The company posted an adjusted quarterly per share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' estimates of $1.39 per share on $9.55 billion in sales, according to LSEG-compiled data.
Thierry Pieton, Medtronic's Chief Financial Officer, mentioned that the company received tariff refunds that nearly offset the duties paid during the quarter. However, future refunds have not been factored into the company's outlook.
Focus on Growth and Market Expansion
Martha emphasized Medtronic's commitment to expanding its presence in large patient segments with significant growth potential. He underscored the company's strategic mergers and acquisitions, which aim to enhance its capabilities in the rapidly evolving medtech landscape.
The company's latest financial projections and strategic investments underscore its confidence in the expanding market for advanced cardiovascular solutions. As Medtronic continues to innovate and invest in new technologies, it positions itself to capitalize on the increasing demand for sophisticated medical devices worldwide.